Javier De Las Rivas

Prof. Dr. Javier De Las Rivas

Bioinformatics and Functional Genomics Group, Cancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC) University of Salamanca (USAL), and Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Cell
Verified
Journal Article
Closed access
TRThomas Rolland
Thomas Rolland
MTMurat Taşan
Murat Taşan
BCBenoit Charloteaux
Benoit Charloteaux
SPSamuel J. Pevzner
Samuel J. Pevzner
QZQuan Zhong
Quan Zhong
MVMarc Vidal
Marc Vidal

8 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
KLKatja Luck
Katja Luck
DKDae-Kyum Kim
Dae-Kyum Kim
LLLuke Lambourne
Luke Lambourne
KSKerstin Spirohn
Kerstin Spirohn
BBBridget E. Begg
Bridget E. Begg
MCMichael A. Calderwood
Michael A. Calderwood

24 June 2010 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
Javier De Las RivasJavier De Las Rivas
Javier De Las Rivas
CFCelia Fontanillo
Celia Fontanillo
8 páginas, 3 figuras, 1 tabla.-- This is an open-access article distributed under the terms of the Creative Commons Attribution License.This work has been supported by funds provided by the Local Government Junta de Castilla y León (JCyL, ref. project: CSI07A09), by the Spanish Ministry of Science and Innovation (MICINN - ISCiii, ref. projects: PI061153 and PS09/00843) and by the European Commission Research Grant PSIMEx (ref. FP7-HEALTH-2007-223411).Peer Reviewe

29 June 2011 in Nature Methods
Verified
Journal Article
Closed access
PDF file
BABruno Aranda
Bruno Aranda
HBHagen Blankenburg
Hagen Blankenburg
SKSamuel Kerrien
Samuel Kerrien
FBFiona Brinkman
Fiona Brinkman
ACArnaud Ceol
Arnaud Ceol
HHHenning Hermjakob
Henning Hermjakob

8 August 2007 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
SOSandra Orchard
Sandra Orchard
LSLukasz Salwinski
Lukasz Salwinski
SKSamuel Kerrien
Samuel Kerrien
LMLuisa Montecchi-Palazzi
Luisa Montecchi-Palazzi
MOMatthias Oesterheld
Matthias Oesterheld
HHHenning Hermjakob
Henning Hermjakob
A wealth of molecular interaction data is available in the literature, ranging from large-scale datasets to a single interaction confirmed by several different techniques. These data are all too often reported either as free text or in tables of variable format, and are often missing key pieces of information essential for a full understanding of the experiment. Here we propose MIMIx, the minimum information required for reporting a molecular interaction experiment. Adherence to these reporting guidelines will result in publications of increased clarity and usefulness to the scientific community and will support the rapid, systematic capture of molecular interaction data in public databases, thereby improving access to valuable interaction data.

18 May 2021 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
Javier De Las RivasJavier De Las Rivas
Javier De Las Rivas
ABAnamaria Brozovic
Anamaria Brozovic
SISivan Izraely
Sivan Izraely
ACAlba Casas-Pais
Alba Casas-Pais
IWIsaac P. Witz
Isaac P. Witz
Angelica Figueroa Conde-ValvísAngelica Figueroa Conde-Valvís
Angelica Figueroa Conde-Valvís
Over the last decade, important clinical benefits have been achieved in cancer patients by using drug-targeting strategies. Nevertheless, drug resistance is still a major problem in most cancer therapies. Epithelial-mesenchymal plasticity (EMP) and tumour microenvironment have been described as limiting factors for effective treatment in many cancer types. Moreover, epithelial-to-mesenchymal transition (EMT) has also been associated with therapy resistance in many different preclinical models, although limited evidence has been obtained from clinical studies and clinical samples. In this review, we particularly deepen into the mechanisms of which intermediate epithelial/mesenchymal (E/M) states and its interconnection to microenvironment influence therapy resistance. We also describe how the use of bioinformatics and pharmacogenomics will help to figure out the biological impact of the EMT on drug resistance and to develop novel pharmacological approaches in the future.